Table 2.

Clinical presentation (23 patients)

No. of patients
ANCA status
    P-ANCA by IIF16 (69.6%)
        MPO ANCA by ELISA9 of 9 (100%)
    C-ANCA by IIF2 (8.6%)
        PR3 ANCA by ELISA1 of 1 (100%)
    negative4 (17.4%)
    not available1 (4.3%)
Extrarenal manifestation of vasculitis
    none15 (65.2%)
    pulmonary hemorrhage6 (26.1%)
    episcleritis1 (4.3%)
    purpura1 (4.3%)
24-h urine protein (g)a4.1 ± 2.7 (1.1–9.4)
Serum albumin (g/dl)3.1 ± 0.6 (1.8–4.2)
Edema13 (56.5%)
Full nephrotic syndrome5 of 16 (31.2%)
Hematuria22 of 22 (100%)
Baseline serum creatinine (mg/dl)b1.6 ± 0.7 (1.0–3.3)
On HD at biopsy11 (47.8%)
Serum creatinine at biopsy in the 12 patients not on HD (mg/dl)4.1 ± 1.9 (1.3–8.7)
  • ANCA, antinuclear cytoplasmic antibody; HD, hemodialysis; IIF, indirect immunofluorescence; MPO, myeloperoxidase; PR3, proteinase 3. Data are mean with range or fraction with corresponding percentage.

  • a Not available in 7 patients, all of whom had 1–3+ protein on urinalysis.

  • b Available in 19 patients.